CL2022002365A1 - Inactivated vaccine against sars-cov-2 virus - Google Patents

Inactivated vaccine against sars-cov-2 virus

Info

Publication number
CL2022002365A1
CL2022002365A1 CL2022002365A CL2022002365A CL2022002365A1 CL 2022002365 A1 CL2022002365 A1 CL 2022002365A1 CL 2022002365 A CL2022002365 A CL 2022002365A CL 2022002365 A CL2022002365 A CL 2022002365A CL 2022002365 A1 CL2022002365 A1 CL 2022002365A1
Authority
CL
Chile
Prior art keywords
cov
virus
vaccine against
inactivated vaccine
against sars
Prior art date
Application number
CL2022002365A
Other languages
Spanish (es)
Inventor
Meinke Andreas
Möhlen Michael
Schlegl Robert
Heindl-Wruss Jürgen
Original Assignee
Valneva Austria Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2021/020313 external-priority patent/WO2021178318A1/en
Application filed by Valneva Austria Gmbh filed Critical Valneva Austria Gmbh
Publication of CL2022002365A1 publication Critical patent/CL2022002365A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20061—Methods of inactivation or attenuation
    • C12N2770/20063—Methods of inactivation or attenuation by chemical treatment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Aquí se describen vacunas contra el SARS-CoV-2 y composiciones y métodos para producir y administrar dichas vacunas a sujetos que las necesitan.Described herein are vaccines against SARS-CoV-2 and compositions and methods for producing and administering such vaccines to subjects in need thereof.

CL2022002365A 2020-04-06 2022-08-30 Inactivated vaccine against sars-cov-2 virus CL2022002365A1 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP20168324 2020-04-06
EP20202118 2020-10-15
EP20211853 2020-12-04
EP21154647 2021-02-01
PCT/US2021/020313 WO2021178318A1 (en) 2020-03-01 2021-03-01 Coronavirus vaccines comprising a tlr9 agonist
EP21160913 2021-03-05

Publications (1)

Publication Number Publication Date
CL2022002365A1 true CL2022002365A1 (en) 2023-02-03

Family

ID=79566178

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022002365A CL2022002365A1 (en) 2020-04-06 2022-08-30 Inactivated vaccine against sars-cov-2 virus

Country Status (13)

Country Link
EP (1) EP3955959A2 (en)
JP (1) JP2023520521A (en)
KR (1) KR20220164500A (en)
CN (1) CN115768469A (en)
AU (1) AU2021253605A1 (en)
BR (1) BR112022020100A2 (en)
CA (1) CA3168784A1 (en)
CL (1) CL2022002365A1 (en)
CO (1) CO2022013715A2 (en)
EC (1) ECSP22072590A (en)
IL (1) IL296072A (en)
MX (1) MX2022012447A (en)
ZA (1) ZA202209826B (en)

Also Published As

Publication number Publication date
AU2021253605A1 (en) 2022-10-06
CN115768469A (en) 2023-03-07
ZA202209826B (en) 2023-05-31
BR112022020100A2 (en) 2022-11-29
JP2023520521A (en) 2023-05-17
EP3955959A2 (en) 2022-02-23
KR20220164500A (en) 2022-12-13
IL296072A (en) 2022-11-01
ECSP22072590A (en) 2022-10-31
CO2022013715A2 (en) 2022-12-30
MX2022012447A (en) 2022-10-27
CA3168784A1 (en) 2021-10-14

Similar Documents

Publication Publication Date Title
ECSP22072586A (en) VACCINE AGAINST SARS-CoV-2 VIRUS WITH CpG ADJUVANT
UY39159A (en) INACTIVATED VACCINE AGAINST SARS-CoV-2 VIRUS
MX2018007627A (en) Zika virus vaccine.
BR112018016755A2 (en) Zica virus vaccine
BR112018013387A2 (en) recombinant vaccination vector, mva virus, vaccine or pharmaceutical composition and kit
PE20151588A1 (en) VACCINE AGAINST DENGUE VIRUS
AR108829A1 (en) VACCINE AGAINST INFECTIOUS BRONCHITIS VIRUS
CO2021003931A2 (en) Dengue Vaccine Unit Dose and Administration
BR112013017171A2 (en) stable immunogenic combination vaccine, stable combination vaccine preparation process, method of using antigenic molecules and method of administration to human subjects
MX2020004633A (en) Method for inactivating zika virus and related methods.
BR112015021523A8 (en) composition of a vaccine against acellular pertussis, and uses of the composition and antigens of bordetella pertussis
CO2022012272A2 (en) Vaccines against coronavirus and methods of use
BR112015022582A2 (en) nucleic acid molecule, plasmid, vaccine, and use of a plasmid
CL2021002582A1 (en) Vaccines against porcine circovirus type 3 (pcv3), their production and uses
BR112022020298A2 (en) VACCINES, ADJUVANTS AND METHODS TO GENERATE AN IMMUNE RESPONSE
MX2022010781A (en) Cpg-adjuvanted sars-cov-2 virus vaccine.
BR112018008697A2 (en) method and kit for vaccination against an autoantigen, use of a kit, and vaccine for use in vaccination.
CO2022013715A2 (en) Inactivated vaccine against sars-cov-2 virus
CL2009000287A1 (en) A composition comprising an inactivated salmonid alphavirus (sav) and at least one component selected from a killed / inactivated bacterium, another inactivated virus, a fungus, a parasite and an antigenic material derived from the above bacterium, virus, fungus or parasite; method to develop the composition and use of sav.
UY38933A (en) CHICUNGUÑA VIRUS-TYPE PARTICULATE VACCINE AND METHODS FOR ITS USE
BRPI0811459A8 (en) VIROSOMIC PREPARATION, USE OF A VIROSOMAL PREPARATION, KIT, AND METHODS TO VACCINATE A HUMAN AGAINST INFLUENZA INFECTIONS, AND TO VACCINATE INDIVIDUALS MAMMALIANS AGAINST INFLUENZA INFECTIONS
CL2015003445A1 (en) Use of horse mackerel necrosis virus (sjnnv) for the protection of fish against infection with red spotted grouper necrosis virus (rgnnv); vaccine comprising sjnnv; and method to protect fish against rgnnv infection.
AR121752A1 (en) INACTIVATED VACCINE AGAINST SARS-CoV-2 VIRUS
BR112022008711A2 (en) METHODS TO PRODUCE A VIRAL VACCINE AND REDUCE VIRAL PARTICLE SIZE
AR121151A1 (en) FORMULATIONS FOR VACCINE AGAINST CORONAVIRUS